Skip to main content

Table 5 Genotypic and immuno-trophic characteristics at the time of genotyping associated with virological suppression after 48 weeks of initiation of the rescue scheme

From: Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure

Viral Load (VL)

Characteristics

Detectable

n (%)

Undetectable

n (%)

PR

PR 95% IC

P-value

Age (years)

    

0, 662a

 18–30

6 (11, 5)

13 (12, 2)

0, 92

0, 45 – 1, 86

 

 31–50

40 (76, 9)

76 (71, 0)

1, 00

 

  > 50

6 (11, 5)

18 (16, 8)

0, 73

0, 35 – 1, 52

 

Gender

    

0, 385a

 Male

36 (69, 2)

81 (75, 7)

0, 81

0, 50 – 1, 29

 

 Female

16 (30, 8)

26 (24, 3)

1, 00

 

VL on genotypic result (copies/ml)

    

0, 752a

  ≤ 10.000

18 (35, 3)

36 (34, 3)

1, 00

 

  > 10.000 a 100.000

20 (39, 2)

47 (44, 7)

0, 90

0, 53 – 1, 52

 

  > 100.000

13 (25, 5)

22 (21, 0)

1, 11

0, 63 – 1, 98

 

CD4 on genotypic result (cells/mm3)

    

0, 796a

  < 200

20 (38, 5)

45 (42, 9)

0, 95

0, 54 – 1, 66

 

 200–350

18 (34, 6)

31 (29, 5)

1, 13

0, 64 – 1, 99

 

  > 350

14 (26, 9)

29 (27, 6)

1, 00

 

Number of NRTI resistance mutations

    

0, 179a

 zero

6 (11, 6)

10 (9, 3)

1, 00

 

  < 3

32 (61, 5)

52 (48, 6)

1, 02

0, 51 – 2, 02

 

  ≥ 3

14 (26, 9)

45 (42, 1)

0, 63

0, 29 – 1, 38

 

N° of thymidine analogue mutation

    

0, 058a

 zero

35 (67, 3)

54 (50, 4)

1, 00

 

  < 3

14 (26, 9)

34 (31, 8)

0, 74

0, 45 – 1, 24

 

  ≥ 3

3 (5, 8)

19 (17, 8)

0, 35

0, 12 – 1, 02

 

Number of NNRTI resistance mutations

    

0, 113a

  ≤ 2

32 (61, 5)

79 (73, 8)

1, 00

 

  > 2

20 (38, 5)

28 (26, 2)

1, 45

0,93 – 2,25

 

Number of PI resistance mutations

    

1, 000b

  ≤ 2

4 (80, 0)

14 (77, 8)

1, 00

 

  > 2

1 (20, 0)

4 (22, 2)

0, 90

0, 13 – 6, 35

 

M184 V/I mutation

    

0, 693a

 Yes

44 (84, 6)

93 (86, 9)

1, 00

 

 no

8 (15, 4)

14 (13, 1)

1, 13

0, 62 – 2, 07

 
  1. aChi-square test bFisher’s exact test, PR prevalence ratio, CI Confidence interval, CD4: CD4 T cells, CV viral load, NNRTI non-nucleoside reverse transcriptase inhibitor, PI protease inhibitor, NRTI nucleoside reverse transcriptase inhibitor